How has Fabry disease knowledge evolved over the past 20 years? Analysis of recent evidence.

Description:
You can now watch an internationally recognized faculty of Fabry disease experts at the Sanofi Genzyme satellite symposium that took place on February 11th 2021, from 12-1 pm EST: “How has Fabry disease knowledge evolved over 20 years? Analysis of recent evidence.”

This Sanofi Genzyme sponsored Satellite Symposium is limited to viewers from outside the United States of America. International participants only.

Supported by Sanofi Genzyme.

Click here to watch video
By clicking on this button you confirm that you are an HCP based OUTSIDE the United States.

Presentations in this session

Introduction and welcome.
Mehdi Namdar.
University Hospital of Geneva, Switzerland.

Major knowledge advances in the last 20 years around Fabry Disease.
Juan M. Politei.
Fundación para el Estudio de las Enfermedades Neurometabólicas, Buenos Aires, Argentina

Major knowledge advances in the last 20 years around Fabry Disease in Nephrology.
Alberto Ortiz.
Jiménez Díaz Foundation and Autonomous University of Madrid, Spain.

Major knowledge advances in the last 20 years around Fabry Disease in Cardiology.
Mehdi Namdar.
University Hospital of Geneva, Switzerland.

Q&A

Faculty

Mehdi Namdar
Mehdi Namdar.
University Hospital of Geneva, Switzerland.

Mehdi Namdar is a senior staff Cardiologist and Interventional Electrophysiologist at the Geneva University Hospitals in Geneva, Switzerland, and Chair at the Medical Faculty of the University of Geneva. He received his

medical training at the University Hospital in Zurich, Switzerland, followed by years of training in Brussels, Belgium (where he obtained his PhD degree, mentored by Prof. Pedro Brugada on electrocardiographic changes in Fabry disease), and Paris, France.

His clinical and scientific work focuses on the mechanisms, diagnosis, and ablation of all types of arrhythmias, and implantation of cardiac devices. One of his main research interests is the investigation of arrhythmogenesis and underlying electrophysiological mechanisms in hereditary cardiomyopathies.

Dr Namdar is the author of more than 90 original articles and an editorial and review board member of numerous scientific cardiovascular journals. He is also an advisory board member and consultant for many cardiovascular pharmaceutical and med-tech companies. Dr Namdar is actively involved in different start-up companies’ patent ownership. He is President of the CHAR Foundation – Swiss Arrhythmia Foundation, a position he has held since 2015.


Juan Manuel Politei

Juan Manuel Politei, MD
Fundación para el Estudio de las Enfermedades Neurometabólicas, Buenos Aires, Argentina

Juan Manuel Politei is Neurologist and Staff Member of Fundación para el Estudio de las Enfermedades Neurometabólicas (FESEN), Neurochemistry Lab. “Dr Nestor Chamoles”, Buenos Aires, Argentina. He also works at the Neurointensivism Section of the Dupuytren Private Clinic and at the CADIMI Myasthenia Gravis Centre, both in Buenos Aires. Dr Politei received his medical degree from the University Institute of Health Sciences, Barcelo Foundation, in Buenos Aires, in 1999. He completed his neurology specialism at Juan Fernandez Hospital, Buenos Aires, in 2004. He teaches at the University Institute of Health Sciences, Barcelo Foundation, the Neurology Department of El Salvador University, and Juan Fernández Hospital, Buenos Aires. He is a member of the Argentine Neurology Society and has published more than 50 papers in peer-reviewed journals on the neurological aspects of Fabry disease. Dr Politei started his activity in Fabry disease in 2002, and to date he has followed more than 80 patients in his own center and has received more 350 patients from Latin America. His current areas of interest in Fabry disease are neuropathic pain, gastrointestinal involvement, and cerebrovascular compromise. He is involved with other lysosomal disorders such as glycogen storage diseases, mucopolysaccharidosis, Niemann Pick disease, leukodystrophies, and neuropathic pain in painful channelopathies.


Alberto Ortiz

Alberto Ortiz.
Jiménez Díaz Foundation and Autonomous University of Madrid, Spain.

Juan Manuel Politei is Neurologist and Staff Member of Fundación para el Estudio de las Enfermedades Neurometabólicas (FESEN), Neurochemistry Lab. “Dr Nestor Chamoles”, Buenos Aires, Argentina. He also works at the Neurointensivism Section of the Dupuytren Private Clinic and at the CADIMI Myasthenia Gravis Centre, both in Buenos Aires. Dr Politei received his medical degree from the University Institute of Health Sciences, Barcelo Foundation, in Buenos Aires, in 1999. He completed his neurology specialism at Juan Fernandez Hospital, Buenos Aires, in 2004. He teaches at the University Institute of Health Sciences, Barcelo Foundation, the Neurology Department of El Salvador University, and Juan Fernández Hospital, Buenos Aires. He is a member of the Argentine Neurology Society and has published more than 50 papers in peer-reviewed journals on the neurological aspects of Fabry disease. Dr Politei started his activity in Fabry disease in 2002, and to date he has followed more than 80 patients in his own center and has received more 350 patients from Latin America. His current areas of interest in Fabry disease are neuropathic pain, gastrointestinal involvement, and cerebrovascular compromise. He is involved with other lysosomal disorders such as glycogen storage diseases, mucopolysaccharidosis, Niemann Pick disease, leukodystrophies, and neuropathic pain in painful channelopathies.

Alberto Ortiz is Chief of Nephrology and Hypertension at the Health Research Institute of the Jiménez Díaz Foundation (IIS-FJD UAM), Madrid, Spain, and Professor of Medicine at the Autonomous University of Madrid (UAM). Professor Ortiz’s research interests include the pathogenesis and treatment of acute kidney injury, diabetic nephropathy and proteinuric chronic kidney disease, vascular injury in kidney disease, Fabry disease, and systems medicine.

He is Editor-in-Chief of the Clinical Kidney Journal, an editorial board member of the Journal of the American Society of Nephrology, a council member of the European Renal Association (ERA-EDTA), a member of European Uremic Toxins (EUTox) Work Group and European Renal Best Practice (ERBP) Organization, coordinator of the Spanish Renal Research Network (REDINREN), ERA-EDTA Award for Research Excellence 2020, Distinguished Fellow of the ERA-EDTA, and corresponding member of the Spanish Royal National Academy of Medicine.

His current h-index is 80/98 (ISI-WOK/Google Scholar), and he has > 60,000 citations (Google Scholar), an accumulated impact factor of > 3,500, and 6 patents or patent applications on therapy for kidney disease.